Clinical trials: Depression, Unipolar
Major Depressive Disorder
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
- Trial name
- NCT00742573
- Testing
- Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B)
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- New York State Psychiatric Institute
Autism Spectrum Disorder, Depression
TMS for Adults With Autism and Depression
The goal of this proposal is to investigate whether a standard rTMS protocol for depression, including multiple sessions applied to left dorsolateral prefrontal cortex (DLPFC) results in reduction of depressive symptoms for adult…
- Conditions
- Autism Spectrum Disorder, Depression, Depressive Disorder, Major Depressive Disorder
- Trial name
- TAD (NCT02939560)
- Testing
- NeuroStar® TMS device (Neuronetics, Atlanta, GA)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
MDD, Citalopram
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment.
- Conditions
- MDD, Citalopram, Major Depressive Disorder
- Trial name
- NCT01557946
- Testing
- citalopram
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mclean Hospital
Mood Disorders, Bipolar Disorder
Technology Enhanced Family Treatment
The investigators propose to enhance the scalability of family-focused therapy (FFT), a 12-session evidence-based therapy for youth at high risk for mood disorders, through augmentation with a novel mobile phone application…
- Conditions
- Mood Disorders, Bipolar Disorder, Major Depression
- Trial name
- NCT03913013
- Testing
- Family-Focused Treatment with MCC App
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Development of Pregnenolone as a Treatment for Depression
Pregnenolone, an over-the-counter supplement, is a naturally occurring neurosteroid made in the adrenal glands and brain. Preclinical research suggests pregnenolone has antidepressant, cognitive enhancing, and neuroprotective…
- Trial name
- NCT03645096
- Testing
- Pregnenolone 500 mg, Pregnenolone 800 mg
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depression in Remission
Feasibility of Adherence to Light Therapy
In this feasibility study, we propose an important question: What factors will affect participant adherence to the daily use of light therapy for maintenance treatment of depression? To answer this question, we will conduct a…
- Trial name
- NCT04944758
- Testing
- Light therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of British Columbia
Major Depressive Disorder
Focal Electroconvulsive Therapy for Depression
This pilot, open label investigation evaluates the safety and efficacy of a new form of electroconvulsive therapy (ECT). Both the efficacy and adverse cognitive effects of ECT are highly contingent on the intracerebral current…
- Trial name
- FEAST (NCT01589315)
- Testing
- focal ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder With Psychotic Features
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
The purpose of this study is to compare the efficacy and tolerability of Seroquel monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus Selective Serotonin Reuptake Inhibitor.
- Trial name
- Seroquel (NCT00955474)
- Testing
- Quetiapine, escitalopram, Sertraline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00839423
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine XL
- Volunteers
- 426 people
- Sponsor
- H. Lundbeck A/S
Sleep Disturbances
Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
To assess effects of brexpiprazole on sleep patterns of depressed patients with sleep disturbances.
- Trial name
- NCT01942733
- Testing
- Brexpiprazole
- Volunteers
- 44 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder.
- Trial name
- RELIANCE-II (NCT04855747)
- Testing
- REL-1017
- Where
- 70 sites in United States
- Volunteers
- 236 people
- Sponsor
- Levomecor Inc.
Seasonal Affective Disorder
Environmental Treatment for Seasonal Affective Disorder (SAD)
The purpose is to study treatments of Seasonal Affective Disorder (SAD).
- Trial name
- NCT00139997
- Testing
- Litebook treatment devices, Inactivated negative ion generator
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 26 people
- Sponsor
- Yale University
Depressive Disorder
Memantine Augmentation of Antidepressants
This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.
- Trial name
- NCT00344682
- Testing
- memantine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Massachusetts, Worcester
Major Depressive Disorder, Cognitive Change
THINC-it Vortioxetine - Sensitivity to Change
The purpose of this study is to evaluate the sensitivity of the THINC-it tool, in measuring change in cognitive deficits in individuals with MDD after receiving vortioxetine.
- Trial name
- NCT03053362
- Testing
- Vortioxetine, THINC-it Tool
- Where
- Canada
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Brain and Cognition Discovery Foundation
Major Depressive Disorder, Depression
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
- Trial name
- RELIGHT (NCT06011577)
- Testing
- REL-1017
- Where
- 36 sites in United States
- Volunteers
- 27 people
- Sponsor
- Levomecor Inc.
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
Improving Attentional and Cognitive Control in the Psychological Treatment of Intrusive Thoughts
The investigators are conducting this study to learn more about the cognitive and attentional processes among individuals with three types of repetitive negative thinking (RNT): mental rituals (as seen in obsessive compulsive…
- Conditions
- Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Major Depressive Disorder
- Trial name
- NCT04225624
- Testing
- Emotion Regulation Therapy - Attention Regulation (AR-ERT), Supportive Psychotherapy (SPT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969150
- Testing
- Levomilnacipran ER
- Where
- 25 sites in United States
- Volunteers
- 362 people
- Sponsor
- Forest Laboratories
Treatment Resistant Depression, Electroconvulsive Therapy
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as…
- Conditions
- Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine
- Trial name
- ELEKT-D (NCT03113968)
- Testing
- electroconvulsive therapy (ECT), Ketamine
- Where
- 5 sites in United States
- Volunteers
- 403 people
- Sponsor
- Bo Hu
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Sleep-disordered Breathing, Major Depressive Disorder
Sleep-Disordered Breathing and PAP in Perinatal Depression
The goal of this study is to understand the contribution of sleep-disordered breathing (SDB) to one of the most common and debilitating adverse pregnancy outcomes, perinatal depression.
- Trial name
- NCT02507297
- Testing
- Positive Airway Pressure (PAP)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan